A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a sudden cutaneous reaction. Bone Marrow Transplantation (2000) 25, 907-908. Keywords: tacrolimus; macrolide; allergy Tacrolimus (FK506) is a macrolide immunosuppressant produced by the fungus Streptomyces tsukubaensis. The drug is indicated for liver transplant rejection prophylaxis and is under investigation for use in kidney, cardiac, pancreas, small bowel, and bone marrow transplantation. Tacrolimus inhibits T lymphocyte activation by binding to an intracellular protein (FKBP), which interacts with calcineurin and subsequently inhibits the phosphatase activity of calcineurin. Without this phosphatase activity, it is thought that the generation of gene transcription for the interleukins (IL-2, ␥-interferon) is inhibited and thus results in decreased T lymphocyte activation.
Tacrolimus (FK506) is a macrolide immunosuppressant produced by the fungus Streptomyces tsukubaensis. The drug is indicated for liver transplant rejection prophylaxis and is under investigation for use in kidney, cardiac, pancreas, small bowel, and bone marrow transplantation. Tacrolimus inhibits T lymphocyte activation by binding to an intracellular protein (FKBP), which interacts with calcineurin and subsequently inhibits the phosphatase activity of calcineurin. Without this phosphatase activity, it is thought that the generation of gene transcription for the interleukins (IL-2, ␥-interferon) is inhibited and thus results in decreased T lymphocyte activation.
Cutaneous reactions to tacrolimus occur in 10-24% of patients and are described as simply 'a rash'. Cutaneous reactions to macrolide antibiotics such as clarithromycin range from mild skin eruptions to Stevens-Johnson syndrome. The mild symptoms resolve when the drug is stopped.
Case report
A 45-year-old woman, was referred to our institution for a haploidentical allogeneic bone marrow transplant for treatment of acute myelogenous leukemia (FAB M4) in second remission. She received a preparative regimen containing thiotepa (5 mg/kg × 1, day −6), cyclophosphamide (60 mg/kg/day × 2, days −5, −4), antithymocyte globulin (equine) (15 mg/kg/day × 2, days −4, −2 and 10 mg/kg/day × 6, days +5 to +10), and total body irradiation (200 cGy × 5 fractions, days −2, −1, 0). For graft-versus-host disease prophylaxis, tacrolimus (FK506) at 0.03 mg/kg/day as continuous infusion was started on day −1.
The patient had a history of allergies to ciprofloxacin, clarithromycin, vancomycin, and allopurinol, all of which caused a rash, apart from vancomycin which caused itching. Upon admission, skin examination was normal, with normal turgor and tone, without presence of petechiae, echymoses, or lesions. With the patient's stated macrolide allergy, we were concerned at starting tacrolimus, so a review of the medical literature was undertaken to look for any reports of cross-reactivity between tacrolimus and clarithromycin. In a thorough review as well as conversations with the manufacturer of tacrolimus, Fujisawa (Deerfield, IL, USA), no such reports had been made during clinical trials or within the post-marketing period.
The decision was made to initiate therapy and monitor the patient closely. Tacrolimus was started as described in the above regimen. The patient also received cytomegalovirus immune globulin, sulfamethoxazole and trimethoprim, fluconazole, methylprednisolone, radiation, ursodeoxycholic acid, famotidine, conjugated estrogen, and alprazolam on the same day. After 3 days she developed an erythematous, follicular rash and the next day, she had diffuse, generalized erythema. Because of the escalating skin problems, the tacrolimus was stopped and replaced with cyclosporine. After 24 h, the erythema had decreased; within 2 more days, the rash had resolved. A skin biopsy was not done. Tacrolimus levels were drawn beginning 48 h after the start of the infusion: the initial level was 8.9 ng/ml, 11.9 ng/ml on the day the rash appeared, and 3.5 ng/ml when the rash had nearly resolved.
Discussion
In summary, the patient was admitted for an allogeneic bone marrow transplant for treatment of acute myelogenous leukemia in second remission. She received tacrolimus for prophylaxis of graft-versus-host disease. Within 72 h of initiation of tacrolimus she developed a diffuse, perifollicular, erythematous rash on her back, arms, hands, and legs; approximately 24 h after stopping the medication, the rash began to subside. It appears that our patient had an allergic reaction to tacrolimus. To date, there have been no reports of cross-sensitivity with tacrolimus and macrolides. It is our opinion that there is a cross-allergenicity between these agents and caution should be used if the decision is made to use tacrolimus in a patient with a macrolide allergy.
